1. Home
  2. SAIA vs CYTK Comparison

SAIA vs CYTK Comparison

Compare SAIA & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Saia Inc.

SAIA

Saia Inc.

HOLD

Current Price

$350.47

Market Cap

8.7B

Sector

Industrials

ML Signal

HOLD

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

HOLD

Current Price

$62.60

Market Cap

8.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SAIA
CYTK
Founded
1924
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Trucking Freight/Courier Services
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.7B
8.0B
IPO Year
2002
2004

Fundamental Metrics

Financial Performance
Metric
SAIA
CYTK
Price
$350.47
$62.60
Analyst Decision
Buy
Strong Buy
Analyst Count
19
16
Target Price
$355.22
$82.38
AVG Volume (30 Days)
442.9K
2.2M
Earning Date
02-10-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
10.58
N/A
Revenue
$3,233,286,000.00
$87,211,000.00
Revenue This Year
$2.30
$339.72
Revenue Next Year
$4.81
$79.08
P/E Ratio
$33.16
N/A
Revenue Growth
1.96
2609.26
52 Week Low
$229.12
$29.31
52 Week High
$538.03
$70.98

Technical Indicators

Market Signals
Indicator
SAIA
CYTK
Relative Strength Index (RSI) 55.88 47.75
Support Level $350.43 $60.30
Resistance Level $363.60 $65.08
Average True Range (ATR) 12.81 2.91
MACD -0.94 -0.01
Stochastic Oscillator 51.40 45.74

Price Performance

Historical Comparison
SAIA
CYTK

About SAIA Saia Inc.

Saia ranks among the 10 largest less-than-truckload carriers in the United States, with more than 200 facilities and a fleet of more than 6,500 tractors and 26,000 trailers. As a national LTL carrier, the firm offers time-definite and expedited options for shipments ranging between 100 and 10,000 pounds. Saia ranks among the top-tier providers in terms of profitability.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: